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Abstract
Background: The TRAPP (Transport protein particle) complex is a conserved protein complex functioning at various steps in
vesicle transport. Although yeast has three functionally and structurally distinct forms, TRAPPI, II and III, emerging evidence
suggests that mammalian TRAPP complex may be different. Mutations in the TRAPP complex subunit 2 (TRAPPC2) cause X-
linked spondyloepiphyseal dysplasia tarda, while mutations in the TRAPP complex subunit 9 (TRAPPC9) cause postnatal
mental retardation with microcephaly. The structural interplay between these subunits found in mammalian equivalent of
TRAPPI and those specific to TRAPPII and TRAPPIII remains largely unknown and we undertook the present study to
examine the interaction between these subunits. Here, we reveal that the mammalian equivalent of the TRAPPII complex is
structurally distinct from the yeast counterpart thus leading to insight into mechanism of disease.
Principal Findings: We analyzed how TRAPPII- or TRAPPIII- specific subunits interact with the six-subunit core complex of
TRAPP by co-immunoprecipitation in mammalian cells. TRAPPC2 binds to TRAPPII-specific subunit TRAPPC9, which in turn
binds to TRAPPC10. Unexpectedly, TRAPPC2 can also bind to the putative TRAPPIII-specific subunit, TRAPPC8. Endogenous
TRAPPC9-positive TRAPPII complex does not contain TRAPPC8, suggesting that TRAPPC2 binds to either TRAPPC9 or
TRAPPC8 during the formation of the mammalian equivalents of TRAPPII or TRAPPIII, respectively. Therefore, TRAPPC2
serves as an adaptor for the formation of these complexes. A disease-causing mutation of TRAPPC2, D47Y, failed to interact
with either TRAPPC9 or TRAPPC8, suggesting that aspartate 47 in TRAPPC2 is at or near the site of interaction with TRAPPC9
or TRAPPC8, mediating the formation of TRAPPII and/or TRAPPIII. Furthermore, disease-causing deletional mutants of
TRAPPC9 all failed to interact with TRAPPC2 and TRAPPC10.
Conclusions: TRAPPC2 serves as an adaptor for the formation of TRAPPII or TRAPPIII in mammalian cells. The mammalian
equivalent of TRAPPII is likely different from the yeast TRAPPII structurally.
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Introduction
Transport protein particle (TRAPP) is a conserved protein
complex that functions in secretory and endocytic pathways [1].
This complex was first identified in yeast [2] and it is now clear
that distinct forms of the TRAPP complex may exist for specific
functions [3,4,5,6]. A total of ten subunits have been identified in
yeast, including Trs20, Trs23, Trs31, Trs33, Trs65, Trs85,
Trs120, Trs130, Bet3 and Bet5. Additional factors, such as a
homolog of Trs20 called Tca17, may also contribute to the
formation and functions of TRAPP [7,8]. Three forms of TRAPP
complex have been identified in yeast so far. The subunits Trs20,
Trs23, Trs31, Trs33, Bet5 and two copies of Bet3 form a six-
subunit core, which contains a total of seven proteins [9]. This six-
subunit core is TRAPPI and has intrinsic guanine nucleotide
exchange activity for the small GTPase Ypt1p/Rab1 [10]. The
two Bet3 subunits within this complex interact specifically with
COPII coat component Sec23 [11], thus facilitating the tethering
function of TRAPPI. TRAPPII contains all the subunits of
TRAPPI with three additional subunits, Trs65, Trs120 and
Trs130 [6]. TRAPPII is required for intra-Golgi traffic and
endosomal traffic in yeast but the precise mechanism(s) of how it
carries out these functions remain(s) unknown [2,4,12]. An
interaction between the mammalian TRAPPII and the COPI
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significance of this interaction remains to be elucidated [13].
Recent evidence suggests the existence of a third form of TRAPP -
TRAPPIII, which consists of the six-subunit core (TRAPPI) plus
Trs85 [5]. Deletion of the TRS85 gene in yeast caused defects in
autophagy [14,15], suggesting the involvement of TRAPPIII in
autophagy.
All TRAPP subunits except Trs65 are conserved from yeast to
mammals [1,16]. Recently, a distantly related human sequence
C5orf44 (FLJ13611) was identified as the human ortholog to
Trs65. This sequence was shown to interact with a number of
known mammalian TRAPP subunits [17]. In mammals, it appears
that TRAPPII is the predominant form but subcellular localization
suggests diverse functions [13,18]. Mammalian TRAPP complex
subunit 3 (TRAPPC3), the homologue of Bet3, is localized largely
to ER exit sites [19], consistent with its unique function binding to
Sec23. Other subunits localize to various structures along the early
secretory pathway including TRAPPC10 (Trs130 in yeast) at the
cis-Golgi [13], TRAPPC9 (Trs120 in yeast) at the ER exit sites
[20], the ER-Golgi intermediate compartments (ERGIC) and cis-
Golgi (unpublished data) and TRAPPC4 (Trs23 in yeast) on COPI
coated vesicles [13]. COPI vesicles bud from ERGIC and carry
cargo proteins to the cis-Golgi [21]. This suggests that mammalian
TRAPPII also functions in the early secretory pathway in
mammalian cells. In particular, the tethering of COPII vesicles
in vitro is mediated by mammalian Bet3 [19], and activation of
Rab1 by immuno-isolated TRAPPII complex has been demon-
strated [13].
TRAPPII differs from TRAPPI by three additional subunits,
Trs65, Trs120 and Trs130. Recently cryo-EM images of purified
yeast TRAPPII showed that Trs120 and Trs130 bind to opposite
sides of the six-subunit core, and evidence of Trs120-Trs130
interaction is not documented in this report [18]. It has been
demonstrated that their mammalian homologues TRAPPC9 and
TRAPPC10 have interaction [13], although how these two
subunits interact with the six-subunit core remains to be
determined. It is possible that the EM data provided too low a
resolution to show this interaction. Furthermore, the presence of
Trs65 is evident in the yeast TRAPPII structure and the main
function of Trs65 is to mediate dimerization of the two TRAPPII
complexes. It is questionable whether TRAPPII is required to
function as a dimer in vivo because Trs65 deletion changed the
apparent molecular weight of TRAPPII from 1000 kDa to
600 kDa in yeast [17] without causing a block in secretion [6].
In mammals, it has been generally assumed that TRAPPII
equivalent only has two additional subunits, TRAPPC9 and
TRAPPC10, because the role of putative mammalian Trs65,
C5orf44, in TRAPPII assembly has not been well characterized. It
is highly questionable that its dimerization function is conserved in
C5orf44, because mammalian TRAPP has an apparent molecular
weight of 600 kDa in a gel filtration column, identical to the size of
yeast TRAPPII isolated in Trs65-deleted strain.
In its primary amino acid sequence, the identifiable domain of
Trs120 resides in the carboxyl terminal part of the yeast molecule,
but this domain is present in the amino terminus of the
mammalian Trs120 (TRAPPC9). This suggests that Trs120 is
structurally distinct between yeast and mammals, and such
structural distinction will likely manifest in the mammalian
TRAPP complex. Further, TRAPPC9 interacts with nuclear
factor kB (NFkB)-inducing kinase (NIK) and IkB kinase ß (IKK-ß)
[22]. This interaction potentiates the NFkB signaling pathway. As
the NFkB signaling pathway does not exist in yeast, this suggests
that Trs120 has acquired novel functions during the course of
evolution.
The mammalian homolog of Trs85 (TRAPPC8) is also distantly
related to the yeast sequence. Yeast Trs85 is thought to be an
autophagy-specific subunit for TRAPPIII. Its main function is to
target TRAPPIII to autophagosomes, so that TRAPPIII can
recruit and activate Ypt1p on autophagosomal membranes.
However, the possibility that Trs85-associated autohphagy defect
is a secondary consequence of its impaired function in ER to Golgi
trafficking has not been ruled out [17]. Nonetheless, TRAPPC8
has been demonstrated to be required for autophagy in
mammalian cells. siRNA depletion of Trs85 resulted in reduced
autophagy as determined by the extent of lipidation of LC3 [23].
However, the existence of an equivalent of TRAPPIII in
mammalian cells has not been established.
Mutations in TRAPP subunits TRAPPC9 and TRAPPC2
have been identified in patients with mental retardation and X-
linked spondyloepiphyseal dysplasia tarda (SEDT), respectively
[24,25,26,27]. TRAPPC9 mutations result in truncation of
the protein. For example, c. 1322 C.T (GenBank Accession
#NM_031466), results in nonsense R475X [25,26]. Another
mutation, R570X, was identified independently by Philippe et al
[24]. Furthermore, a four-nucleotide deletion results in a stop
codon after the codon encoding leucine 772 [26], henceforth
known as L772D. Some of these truncated TRAPPC9 proteins
showed reduced activation of NFkBp a t h w a y s[ 2 4 , 2 6 ] ,a l t h o u g h
impaired vesicle trafficking has not been ruled out. Its homologue
TRS120 gene is essential in yeast, and therefore, TRAPPC9 is
likely essential. Truncation of this protein could still preserve its
major function, but defects in vesicle trafficking may impair
neuronal development, leading to its associated intellectual
disabilities. Therefore, it is important to characterize how
truncation mutants of TRAPPC9 affect the structure and
function of TRAPPII in the early secretory pathway.
Mutations in the TRAPPC2 gene locus have been identified in
patients with X-linked spondyloephiphyseal dysplasia tarda
(SEDT), and therefore TRAPPC2 was also named sedlin [27].
Of the disease-causing mutations identified so far, the majority
result in early termination during translation, leading to
degradation of partially translated peptides [27,28,29,30,31,
32,33,34]. Of four missense mutations identified in TRAPPC2,
recent biochemical analysis revealed that three of these mutations,
S73L, F83S and V130D, caused misfolding of the mutant protein,
invoking the protein degradation pathway when the GFP-tagged
mutant proteins were overexpressed in COS cells [35]. Further-
more, these mutants also failed to bind to some of the known
interacting proteins of TRAPPC2, including Myc promoter-
binding protein 1 (MBP1), pituitary homeobox 1 (PITX1) and
steroidogenic factor 1 (SF1) [28]. As mutant TRAPPC2 proteins
are more prone to degradation than the wildtype protein, we
suspect that the loss of interaction between mutant TRAPPC2 and
its binding proteins is due to protein degradation. The remaining
TRAPPC2 mutant, D47Y, is not as extensively degraded as the
other three TRAPPC2 mutants. Except a slightly higher affinity to
Bet3 in vitro [35], the reason why D47Y causes SEDT has not
been thoroughly explored.
In this paper, we identify TRAPPC2 as the major adaptor
protein for the interaction between the six-subunit TRAPP
core and TRAPPC9 and/or TRAPPC8. Missense mutation,
D47Y, showed dramatically reduced binding to TRAPPC9
and TRAPPC8, suggesting the formation of TRAPPII or
TRAPPIII is impaired in SEDT patients. Furthermore, we also
determined the effect of disease-causing mutations in
TRAPPC9 on the formation of TRAPPII complex by studying
the ability of TRAPPC9 mutants to bind to TRAPPC2 and
TRAPPC10.
Adaptor Function of TRAPPC2
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TRAPPC2 interacts with TRAPPC9
We first investigated which subunits of the six-subunit core bind
to TRAPPII specific subunits TRAPPC9 and TRAPPC10.
TRAPPC10 was previously shown to interact with TRAPPC9 in
the mammalian system, but was shown to directly contact the six-
subunit core complex in yeast TRAPPII. In mammalian cells, it
has not been determined whether other subunits can also bind to
TRAPPC10. To test the interactions, we transfected Myc-tagged
cDNA encoding various TRAPP subunits together with GFP-
TRAPPC10, immunoprecipitated the Myc-tagged proteins with
anti-Myc IgG and determined if GFP-TRAPPC10 was present in
the pull-downs. As shown in Figure 1A, TRAPPC10 interacts only
with TRAPPC9 (top panel, Figure 1A). Although other TRAPP
subunits may interact very weakly with TRAPPC10, these
interactions were not consistently observed like TRAPPC9.
Therefore, we conclude TRAPPC10 interacts only with
TRAPPC9. This result suggests that mammalian TRAPPC10
may not bind to the six-subunit core the same way as the yeast
complex. As TRAPPC10 only binds to TRAPPC9, we therefore
hypothesized that TRAPPC9 binds directly to the six-subunit core,
bringing along TRAPPC10 to the complex. To test this, we
repeated the co-immunoprecipitation (co-IP) experiment by co-
transfecting GFP-TRAPPC9 with various Myc-tagged TRAPP
subunits. As shown in Figure 1B, TRAPPC2 and to a lesser extent,
TRAPPC6B (Trs33B in yeast), were able to specifically pull down
TRAPPC9 (Figure 1B, top panels). Here, we have established that
a direct interaction between TRAPPC2 and TRAPPC9 is the
physical link between the six-subunit core and the TRAPPII-
specific subunits in mammalian TRAPP. TRAPPC10 is indirectly
associated with the core via TRAPPC9.
TRAPPC2 interacts with TRAPPC8
Although mammalian TRAPPC8 has been postulated to be a
subunit of TRAPP in a complex that functions similarly to the
yeast TRAPPIII, mammalian TRAPPIII has never been demon-
strated to exist. To systematically test how TRAPPC8 binds to
TRAPPI to form the mammalian equivalent of TRAPPIII, we
decided to test the interaction of TRAPPC8 with individual
TRAPP subunits. During the course of establishing conditions for
transfecting various DNA constructs to COS1 cells for overex-
pression, we noticed that TRAPPC2 protein expression was
elevated when the same cells were co-expressed with TRAPPC8,
but not with TRAPPC9. A careful determination of this effect is
demonstrated in Figure 2. When an increasing amount of GFP-
TRAPPC8 cDNA was co-transfected with constant amount of
Myc-TRAPPC2 cDNA, the level of Myc-TRAPPC2 protein
increased (Figure 2A, top panel). This effect was not observed
when we tested another TRAPP subunit, TRAPPC9. An
increased amount of GFP-TRAPPC9 did not increase the protein
expression level of the co-transfected Myc-TRAPPC2 cDNA
(Figure 2B, top panel). These results suggest that TRAPPC8 is
directly interacts with TRAPPC2. When degradation-prone
mutants of Myc-TRAPPC2 were co-transfected with GFP-
TRAPPC8, the expression level of these mutants significantly
increased as compared to samples co-transfected with GFP-
TRAPPC9 (Supplementary Figure S1), suggesting that TRAPPC8
can slow the degradation of TRAPPC2. This finding is not
altogether surprising in view of the fact that TRAPPC8 has been
demonstrated to be involved in autophagy.
In cells co-transfected with GFP-tagged TRAPPC8 and various
Myc-tagged TRAPP subunits, we performed a co-IP experiment
using antibody against c-Myc and determined whether any
TRAPP subunit can pull down GFP-TRAPPC8. TRAPPC2 and
TRAPPC3 were able to pull down GFP-TRAPPC8, with
TRAPPC2 having a stronger interaction (Figure 2C). These
results suggest that TRAPPC2 serves as the adaptor that links
either TRAPPC9 or TRAPPC8 to the core resulting in the
mammalian equivalents of TRAPPII and TRAPPIII, respectively.
If this hypothesis is correct, we will expect that TRAPPC2 cannot
bind to both TRAPPC8 and TRAPPC9 at the same time. To test
this notion, we performed immunoprecipitation using antibody
against TRAPPC9 to isolate endogenous TRAPPC9-containing
TRAPP complex, and determined whether TRAPPC8 is present
in the isolated TRAPP complex (Figure 3). Anti-TRAPPC9
antibody (Figure 3, lane 3), but not control antibody against
LAMP2 (Figure 3, lane 2), could immunoprecipitate endogenous
TRAPP complex from HEK293 cell lysate, as indicated by the
presence of TRAPPC2. TRAPPC8, however, was not present in
this TRAPPC9-positive TRAPP complex, confirming TRAPPC9
and TRAPPC8 do not co-exist in the same TRAPP complex in
vivo.
A disease-causing mutant of TRAPPC2 fails to interact
with either TRAPPC9 or TRAPPC8
We recently characterized four missense mutations of
TRAPPC2 [35]. Three of these mutations, S73L, F82S and
Figure 1. Interactions between putative TRAPPII specific
subunits and TRAPPI core subunits. A. GFP-tagged TRAPPC10
was co-transfected with the indicated Myc-tagged TRAPPI core subunits
in COS cells for co-IP with antibody against c-Myc. The presence of
pulled down TRAPPC10 was detected by immunoblotting with anti-GFP
antibody (top panel). The amount of precipitated Myc-tagged proteins
is shown in second panel from the top. The levels of protein expression
in the transfected lysates are shown in bottom two panels. B. GFP-
tagged TRAPPC9 and indicated Myc-tagged TRAPPI core subunits were
co-transfected into COS cells. Co-IP and subsequent detection by
immunoblotting was performed as above. The experiments shown are
representatives of three independent experiments.
doi:10.1371/journal.pone.0023350.g001
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missense mutation, D47Y, did not cause extensive protein
degradation but has been implicated to affect the TRAPP complex
dynamics because there is a change in the binding affinity of this
mutant to TRAPPC3. After identifying TRAPPC2 as the binding
partner of TRAPPC9 and TRAPPC8, we wanted to test whether
the D47Y mutant impairs the interaction with either of these
proteins. When the Myc-tagged wildtype or D47Y TRAPPC2
cDNA was co-expressed with GFP-tagged TRAPPC9 or
TRAPPC8, wildtype TRAPPC2 was able to pulldown TRAPPC9
or TRAPPC8 (Figure 4A, lanes 1 and 3, respectively). However,
D47Y showed a dramatically reduced affinity for TRAPPC9 and
TRAPPC8 (Figure 4A, lanes 2 and 4, respectively). In this
experiment, we adjusted the level of protein expression of
TRAPPC2 proteins by the amount of DNA used in our
transfection. The levels of protein expression for these proteins
are comparable in the lysates used for co-immunoprecipitation
(Figure 4A, lanes 5–8). When the degree of binding by D47Y and
by wildtype TRAPPC2 was quantified, it was clear that D47Y had
about 21% and 7% of the wildtype protein for its affinity to
interact with TRAPPC9 and TRAPPC8, respectively (Figure 4B).
This result indicates that the adaptor function of TRAPPC2 is
compromised in the D47Y mutation. D47Y may impair the
formation of TRAPP complex(es) that contain(s) TRAPPC9 or
TRAPPC8, causing the SEDT phenotype in patients with this
mutation. To investigate the effect of D47Y in vivo, we
overexpressed this mutant in COS cells and determined its effect
on the Golgi (Figure 4C, left panels). Golgi marker Golgin-97
appears as a large dot-like structure in COS cells (arrows,
Figure 4C, left panels). However, the signal is fragmented in cells
expressing either wildtype or D47Y mutant of TRAPPC2. Upon
careful quantification, we observed that D47Y mutant had a more
disruptive effect on the integrity of the Golgi than wildtype
protein. 50% of the D47Y overexpressing cells have fragmented
Golgi, as compared to 32% and 6.2% for wildtype TRAPPC2
overexpressing cells and non-transfected cells, respectively
(Figure 4C, right panel). TRAPPC9 localization was also disrupted
by D47Y more severely than wildtype protein (Figure 4D). 62% of
the cells overexpressed with D47Y having fragmented TRAPPC9
localization, compared to 47% cells with overexpression of
wildtype TRAPPC2 (Figure 4D, right panel). These results
indicate that D47Y mutant, when overexpressed, can act as a
dominant negative fashion to interfere with the assembly of
TRAPPII or TRAPPIII.
Disease-causing mutations in TRAPPC9 reduce the
binding affinity of the mutant protein to TRAPPC10 and
TRAPPC2
Another genetic disease caused by mutations in TRAPP subunits
is a subset of intellectual disability with postnatal microcephaly.
Mutations in TRAPPC9 have been isolated in susceptible
individuals. We characterized the effect of two such mutations in
TRAPPC9 with respect to their abilities to bind to TRAPPC2 and
TRAPPC10. The mutations tested result in truncation of the
protein (see Introduction). In a co-IP experiment similar to the ones
described in Figure 1, we detected a drastic reduction in the
interaction betweenmutantTRAPPC9andTRAPPC2 (Figure5A).
Both GFP-tagged TRAPPC9 mutant proteins have slightly higher
but comparable levels of protein expression to the GFP-tagged
wildtype protein when expressed in COS1 cells, but the affinity of
Figure 2. TRAPPC8 interacts mainly with TRAPPC2. A. Increasing
amounts of GFP-TRAPPC8 cDNA were co-transfected with a constant
amount of Myc-TRAPPC2 and Myc-TRAPPC9. The levels of protein
expression of all three TRAPP subunits were determined by immuno-
blotting the lysates of the transfected cells. B. Increasing amounts of
GFP-TRAPPC9 cDNA were co-transfected with a constant amount of
Myc-TRAPPC2 and Myc-TRAPPC8. C. GFP-tagged TRAPPC8 and the
indicated Myc-tagged TRAPPI core subunits were co-transfected into
COS cells. Co-IP and subsequent detection by immunoblotting was
performed as in Figure 1. The experiments shown are representatives of
three independent experiments.
doi:10.1371/journal.pone.0023350.g002
Figure 3. Native TRAPP complex containing TRAPPC9 does not
contain TRAPPC8. Native TRAPP complex was isolated by IP using
antibody against TRAPPC9 (lane 3). The presence of TRAPPC9 (top
panel), TRAPPC2 (bottom panel) and TRAPPC8 (middle panel) was
detected by immunoblotting using antibodies specific to these
proteins. IP using antibody against lysosomal marker LAMP2 serves as
negative control (lane 2). HEK293 lysate used in this experiment
(approximately 1% of input) is shown in lane 1. The experiment shown
is a representative of two independent experiments.
doi:10.1371/journal.pone.0023350.g003
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compared to wildtype protein. For R475X, its affinity to TRAPPC2
is reduced to a level below the detection limit of this experiment.
Myc-TRAPPC2 failed to pull down negative control protein GFP-
GAP273, a GFP fusion protein containing the carboxyl terminus
273 residues of ARFGAP1 [36,37]. ARFGAP1 does not interact
with the TRAPP complex (unpublished data). These mutants also
failed to bind to TRAPPC10 as Myc-TRAPPC10 could not pull
down either R475X or L772D (Figure 5B). These results suggest
that TRAPPC9 interacts with TRAPPC2 and TRAPPC10 at the
carboxyl terminus of the protein that is downstream of leucine 772.
Discussion
The present report describes the role of TRAPPC2 as an
adaptor for the TRAPP complex in mammalian cells, mediating
interactions with both TRAPPC9 and TRAPPC8. Given the small
size of mammalian TRAPPC2 (16 kDa), we expected this subunit
could not simultaneously interact with both TRAPPC9 and
TRAPPC8. Indeed, TRAPP complex isolated by immunoprecip-
itation with antibody against TRAPPC9 was devoid of detectable
TRAPPC8, suggesting TRAPPC2 cannot bind to both proteins at
the same time. This biochemical property seems to be conserved
from the yeast protein as mass spectrometry analysis of HA-tagged
TRAPPC8 immuno-isolated protein complex did not recover any
sequence of TRAPPII-specific subunits [17]. TRAPPC2 is not
required for Ypt1p/Rab1 GEF activity, making it the ideal subunit
to serve as an adaptor for the association with TRAPPII or
TRAPPIII specific subunit. Weak but observable interaction
between TRAPPC6B and TRAPPC9 was also detected, suggest-
ing that contacts between TRAPPC9 and the six-subunit core
complex are more extensive than just directly with TRAPPC2.
Our result is only partially consistent with a recent report
suggesting that yeast Trs120 interacts with the six-subunit core
Figure 4. TRAPPC2(D47Y) mutant shows a reduced binding capacity for TRAPPC9 and TRAPPC8. A. Lysates from co-transfections of
GFP-TRAPPC9 or -TRAPPC8 with either Myc-TRAPPC2 or -TRAPPC2(D47Y) were subjected to IP using anti-Myc antibody. Wildtype Myc-TRAPPC2 was
able to pull down GFP-TRAPPC9 (lane 1) and GFP-TRAPPC8 (lane 3). D47Y mutant, however, showed drastically reduced ability to pull down GFP-
TRAPPC9 (lane 2), and failed to pull down GFP-TRAPPC8 (lane 4). The expression levels of these proteins are shown in lanes 5–8. B. A quantification of
the degree of binding was performed using data collected from three experiments similar to the one shown in A. The intensity of the TRAPPC8 or
TRAPPC9 co-precipitated by D47Y is expressed as a percentage of the wildtype TRAPPC2 binding in each co-IP experiment. Error bars=S.E.M. C. COS
cells transfected with wildtype or D47Y Myc-tagged TRAPPC2 were stained with antibodies against Golgin-97 and AF488-secondary antibody (green
signal, left panels). Myc-TRAPPC2 expression was detected with TRITC-conjugated 9E10 antibody (red signals, left panels). Golgi fragmentation was
quantified by counting cells with fragmented Golgin-97 signals (right panel). In three independent experiments, the total number of cells counted is
352 (non-transfected), 277 (wildtype) and 323 (D47Y). Error bar=S.E.M. D. CHO cells transfected with wildtype or D47Y Myc-tagged TRAPPC2 were
stained with antibodies against TRAPPC9 and AF488-secondary antibody (top left panels). The expression of Myc-tagged TRAPPC2 was detected by
TRITC-9E10 (red) (bottom left panels). The ability of wildtype or D47Y to disrupt the native localization of TRAPPC9 was quantified using images
obtained similarly to those shown in the top panels (right panel). A total of 119, 98 and 149 cells were counted in D47Y, wildtype TRAPPC2, and non-
transfected CHO cells, respectively.
doi:10.1371/journal.pone.0023350.g004
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with the six-subunit core from the opposite side where Trs20 is
located [18]. This report analyzed the organization of yeast
TRAPPII complex by single particle EM. We hypothesize that
TRAPPC9 somehow wraps around the six-subunit core with
contact points at residues from TRAPPC2 and TRAPPC6B, and
possibly other subunits whose interactions with TRAPPC9 are too
weak to be detected in our assay system. Our interaction studies,
therefore, indicate that the possible locations of TRAPPC9 and
TRAPPC10 relative to the six-subunit core are slightly different
from the yeast TRAPPII structure (Figure 6). There has likely been
an evolutionary divergence between yeast Trs120 and Tra130 and
their human counterparts resulting in a slightly different TRAPPII
structural organization.
Suchnotionis supportedbythefact that theconserved domainin
mammalian TRAPPC9 is at the carboxyl-terminus, whereas the
same domain in yeast Trs120 is at the amino-terminus. This Trs120
conserved domain (pfam: 08626; CDD:149620) contains approx-
imately 200 to 300 residues depending on the species. In the human
sequence (gi:190359999), the conserved domain encompasses
residues 606 to 923, whereas in yeast S. cerevisiae, the corresponding
domain is found in the amino-terminal 186 residues of the protein
(gi:74610391). No homology is found outside this domain.
Supporting our hypothesis that TRAPPC2 is a subunit serving
an adaptor-like function for linking TRAPPC9 or TRAPPC8 to
the six-subunit core is the observation that a disease-causing
mutation of TRAPPC2, D47Y, is incapable of interacting with
both TRAPPC9 and TRAPPC8. This result suggests that D47 is
at or very near the point of interaction. Structurally, D47 is a
conserved residue that is exposed on the surface of the protein
implicated in protein-protein interactions [9,35]. It has been
previously demonstrated that a loss of TRAPPC2 function, due to
misfolding and degradation of the mutant TRAPPC2 protein,
cause SEDT. In the present study, we have provided evidence the
impairment of TRAPPII and/or TRAPPIII formation and their
associated functions could be the cause of SEDT. In a similar
experiment, we have further identified that the carboxyl terminus
of TRAPPC9 is required for its interaction with TRAPPC2 and
TRAPPC10, as deletional mutants of this domain found in some
patients with intellectual disability failed to interact with
TRAPPC2 or TRAPPC10. This suggests that in patients suffering
from TRAPPC9-associated congenital intellectual disability,
TRAPPII function must be compromised.
Taken together, mammalian TRAPPC2 serves as adaptor for
the formation of the mammalian equivalents of TRAPPII and
TRAPPIII by interacting with TRAPPC9 and TRAPPC8,
respectively. This finding provides a biochemical explanation to
the disease causes of SEDT and TRAPPC9-associated congenital
intellectual disability.
Materials and Methods
DNA
We ordered PCR primers specific for the cDNAs of various
mammalian TRAPP subunits and performed PCR amplification
of these sequences for subcloning. The sequences were subcloned
into pCMV-Myc (Clontech) or peGFP-Cx vector (Clontech) for
mammalian expression. The reading frames of these genes were
maintained to ensure Myc-tagged or GFP-tagged fusion proteins
will be expressed after transfection. Sequencings of the resulting
constructs were performed to confirm no PCR-generated
mutation in the sequences. Of note, we used an isoform of human
TRAPPC9 that contain 944 amino acid residues. The sequence
corresponds to the carboxyl terminal 944 residues of TRAPPC9
(NM_001160372.1) and uses Met249 as start codon. This
sequence was originally identified along with the cloning of a
nearby gene KCNK9 potassium channel by exon trapping [38].
Antibodies
Mouse monoclonal antibody against c-Myc, 9E10 (sc-40), 9E10-
conjugated with TRITC, and rabbit polyclonal antibody against
GFP (sc-8334) were purchased from Santa Cruz Biotechnology,
Inc. (CA, USA). Monoclonal antibody against Golgin-97, CDF4,
was a gift from Dr. Wing Keung Liu’s laboratory (The Chinese
University of Hong Kong), and was originally purchased from
Invitrogen. Rabbit polyclonal antibody against TRAPPC9,
TRAPPC2 and TRAPPC8 were developed by immunizing rabbits
with bacterially overexpressed and purified recombinant proteins.
For TRAPPC2, His6-tagged full-length protein was used for
immunization. For TRAPPC8, a fragment from residue 1286 to
Figure 5. Disease-causing deletional mutants of TRAPPC9 fail
to bind to TRAPPC2 or TRAPPC10. A. GFP -GAP273, -TRAPPC9,
-TRAPPC9(L772D) and -TRAPPC9(R475X) were tested for the interaction
with Myc-tagged TRAPPC2. The levels of protein expression in the
transfected lysates are shown in lanes 1 to 4. Lanes 5 to 8 are
immunoprecipitants. Full-length TRAPPC9 was efficiently pulled down
by Myc-TRAPPC2 (lane 6), but not the deletion mutants of TRAPPC9
(lane 7 and 8), or negative control GFP-GAP273 (lane 5). B. Full-length
and deletional mutants of TRAPPC9 were tested for the interaction with
Myc-tagged TRAPPC10. The levels of protein expression in the
transfected lysates are shown in lanes 1 to 4. Lanes 5 to 8 are
immunoprecipitants. Full-length TRAPPC9 was efficiently pulled down
by Myc-TRAPPC10 (lane 6), but not the deletional mutants (lane 7 and
8), or negative control GFP-GAP273 (lane 5). The experiments shown are
representatives of two independent experiments.
doi:10.1371/journal.pone.0023350.g005
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(MBP) was purified and used for immunization. For TRAPPC9, a
fragment of 300 residues from the carboxyl terminus of the protein
was fused with GST and the fusion protein was used for
immunization. Antisera generated from these immunizations were
collected after three or four immunity boosts. Antibodies specific
to TRAPPC9 were purified by incubating the 2–3 ml of anti-
serum with a piece of nitrocellulose membrane containing 1 mg of
antigen protein for one hour at room temperature. After brief
washes, the bound antibodies were eluted from the nitrocellulose
membrane by 0.1 M glycine, p.H. 2.0. The eluted antibody
solution was neutralized with appropriate amount of Tris, p.H.
8.8, dialyzed against PBS and concentrated for storage.
Cells and culture media
COS1 cells, originally from the ATCC, were maintained in
Debucco’s minimum essential medium (DMEM) (Invitrogen)
supplemented with 10% fetal bovine serum (FBS) (Invitrogen).
Sequence analysis
Sequence analysis was performed using the Homologene
database from NCBI.
Transfection
Transfections of COS1 cells were carried out using polyethy-
lenimine (PEI) method [39]. Briefly, for each 10 cm tissue culture
plate of COS1 cells, a total of 10 mg of the plasmid DNA was
mixed with 30 mg of PEI (branched, 25 kDa, Sigma, 408727) in
0.8 ml of PBS. After 20 minutes, the PEI:DNA complex was
added to the cells and incubated for 5–6 hours. The transfection
medium was replaced with fresh medium for an addition 24–
36 hours and the transfected cells were harvested for analysis.
Immunoprecipitation
COS1 cells transfected with the indicated DNA plasmids were
lysed with 1 ml of lysis buffer [20 mM Tris, pH 8.0, 100 mM
NaCl, 0.1% NP-40 and 16protease inhibitor cocktail CompleteH
(Roche)]. The cells were scrapped from the 10 cm plates and
collected in 1.5 ml tubes. After brief vortex, the lysates were
centrifuged at 7600 g at 4uC for 10 minutes. The supernatants
were collected and subjected to immunoprecipitation using 1–2 mg
of anti-c-Myc antibody and 20 ml of protein-A sepharose slurry
(Sigma, P3391). After at least 3 hours of incubation at 4uC with
agitation, the immunoprecipitants were washed three times with
lysis buffer and once with 20 mM Tris, pH 8.0 and 100 mM
NaCl. 30 mlo f2 6 SDS sample buffer were added to each
immunoprecipitant and the samples were subjected to SDS-PAGE
and immunoblotting analysis. For immunoprecipitation of
TRAPP complex with anti-TRAPPC9 antibody, lysates generated
from approximately 2610
7 HEK293 cells were subjected to
immunoprecipitation using antibody against TRAPPC9, or
against LAMP2 (as control). The rest of the procedures are
Figure 6. Schematic diagram of the yeast and mammalian TRAPP complexes. A. Schematic diagramof yeast TRAPP complexes. B. Schematic
diagram of the putative mammalian TRAPP complexes. The subunits that interact with TRAPPII- or TRAPPIII- specific subunits are labeled in yellow.
doi:10.1371/journal.pone.0023350.g006
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immunoblot data, the X-ray film was first scanned in a Bio-Rad
GS-800 densitometer. The intensity of the signals was quantified
by AlphaEaseFC 4.0 (Alpha Innotech Corp.)
Fluorescence microscopy
Immunofluorescence staining. COS or CHO-K1 cells,
seeded in 12 mm glass cover slips and transiently transfected with
Myc-tagged TRAPPC2, were fixed with 220uC methanol for
5 minutes, re-hydrated and blocked with PBS plus 1% BSA for
20 minutes. Then the cells were stained with the indicated
antibodies at concentration of 1 mg/ml diluted in PBS plus 1%
BSA. After 30 minutes incubation, the cells were washed three
times with PBS plus 1% BSA. Goat anti- mouse IgG conjugated
with Alexa fluor 568 (1:1000 dilution) was applied to the samples.
After 30-minute incubation, the samples were washed 4 times
before they were mounted on glass slide in Fluoromount-G
(Southern BioTech, USA, 0100-01) for microscope visualization.
Fluorescence microscopy visualization and image
capture. Fluorescence signals were visualized and acquired in
a Carl Zeiss LSM-5 laser scanning confocal microscope with 636
objective lens. The images were processed with Adobe Photoshop
7.0.
Supporting Information
Figure S1 TRAPPC8 protects TRAPPC2 mutant from
protein degradation. TRAPPC9 or TRAPPC8 was co-
transfected with various mutants of TRAPPC2 using the same
amount of TRAPPC2 cDNA. The relative protein expression
levels of the wildtype TRAPPC2 or the indicated mutants were
determined by immunoblotting.
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